UCB’s Bimzelx is firmly on physicians’ radars, with Spherix Global Insights finding that awareness of the drug was tracking ...
IL-17A inhibitors such as Novartis’ Cosentyx (secukinumab) and Eli Lilly’s Taltz (ixekizumab) – as well as IL-23 inhibitors like J&J’s Stelara follow-up Tremfya (guselkumab) and AbbVie’s ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback